 3. Patients who have taken any medication classified as a strong CYP3A4 inducer within one week of Study Day 1 or 5 halflives whichever is longer or use of a strong or moderate CYP3A4 inhibitor within one week of Study Day 1 or 5 halflives whichever is longer see Appendix 2. 